Enterprise Value

1.927B

Cash

659.1M

Avg Qtr Burn

-32.13M

Short % of Float

10.84%

Insider Ownership

4.71%

Institutional Own.

99.21%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Birtamimab Details
Rare diseases, Amyloid light chain amyloidosis

Phase 3

Data readout

NNC6019 (PRX004) Details
Rare diseases, Transthyretin amyloidosis

Phase 2/3

Data readout

Prasinezumab (alpha-synuclein) Details
Neurodegenerative disease, Parkinson's disease

Phase 2

Data readout

Phase 1

Data readout

PRX005 (anti-tau) Details
Alzheimer's disease

Phase 1

Update